M
Michael J. Overman
Researcher at University of Texas MD Anderson Cancer Center
Publications - 444
Citations - 19133
Michael J. Overman is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 56, co-authored 367 publications receiving 13311 citations. Previous affiliations of Michael J. Overman include University of Texas at Austin & City of Hope National Medical Center.
Papers
More filters
Journal ArticleDOI
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman,Ray McDermott,Joseph Leach,Sara Lonardi,Heinz-Josef Lenz,Michael A. Morse,Jayesh Desai,Andrew G. Hill,Michael D. Axelson,Rebecca A. Moss,Monica V. Goldberg,Z. Alexander Cao,Jean Marie Ledeine,G. Maglinte,Scott Kopetz,Thierry André +15 more
TL;DR: Nivolumab provided durable responses and disease control in pre-treated patients with dMMR/MSI-H metastatic colorectal cancer, and could be a new treatment option for these patients.
Journal ArticleDOI
Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer
Michael J. Overman,Sara Lonardi,Ka Yeung Mark Wong,Heinz-Josef Lenz,Fabio Gelsomino,Massimo Aglietta,Michael A. Morse,Eric Van Cutsem,Ray McDermott,Andrew Hill,Michael B. Sawyer,Alain Hendlisz,Bart Neyns,Magali Svrcek,Rebecca A. Moss,Jean Marie Ledeine,Z. Alexander Cao,Shital Kamble,Scott Kopetz,Thierry André +19 more
TL;DR: Indirect comparisons suggest combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile.
Journal ArticleDOI
Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy
Scott Kopetz,George J. Chang,Michael J. Overman,Cathy Eng,Daniel J. Sargent,David W. Larson,Axel Grothey,Jean Nicolas Vauthey,David M. Nagorney,Robert R. McWilliams +9 more
TL;DR: Profound improvements in outcome in metastatic CRC seem to be associated with the sequential increase in the use of hepatic resection in selected patients and advancements in medical therapy between 1998 and 2006.
Journal ArticleDOI
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Al B. Benson,Alan P. Venook,Mahmoud M. Al-Hawary,Mustafa A. Arain,Yi Jen Chen,Kristen K. Ciombor,Stacey Cohen,Harry S. Cooper,Dustin A. Deming,Linda Farkas,Ignacio Garrido-Laguna,Jean L. Grem,Andrew J. Gunn,J. Randolph Hecht,Sarah E. Hoffe,Joleen M. Hubbard,Steven C. Hunt,Kimberly L. Johung,Natalie Kirilcuk,Smitha S. Krishnamurthi,Wells A. Messersmith,Jeffrey A. Meyerhardt,Eric D. Miller,Mary F. Mulcahy,Steven J. Nurkin,Michael J. Overman,Aparna Raj Parikh,Hitendra Patel,Katrina S. Pedersen,Leonard B. Saltz,Charles Schneider,David Shibata,John M. Skibber,Constantinos T. Sofocleous,Elena M. Stoffel,Eden Stotsky-Himelfarb,Christopher G. Willett,Kristina M. Gregory,Lisa A. Gurski +38 more
TL;DR: The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options for the treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section as discussed by the authors.
Journal ArticleDOI
Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases
Dan G. Blazer,Yoji Kishi,Dipen M. Maru,Scott Kopetz,Yun Shin Chun,Michael J. Overman,David R. Fogelman,Cathy Eng,David Z. Chang,Huamin Wang,Daria Zorzi,Dario Ribero,Lee M. Ellis,Katrina Y. Glover,Robert A. Wolff,Steven A. Curley,Eddie K. Abdalla,Jean Nicolas Vauthey +17 more
TL;DR: Evaluated patients who underwent preoperative irinotecan- or oxaliplatin-based chemotherapy, followed by resection of colorectal liver metastases found that degree of pathologic response represents a new outcome end point for prognosis after resections of CLM.